Xiaoxing Feng

893 total citations
29 papers, 640 citations indexed

About

Xiaoxing Feng is a scholar working on Biotechnology, Molecular Biology and Oncology. According to data from OpenAlex, Xiaoxing Feng has authored 29 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Biotechnology, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Xiaoxing Feng's work include Cancer Research and Treatments (12 papers), Neuroblastoma Research and Treatments (6 papers) and PARP inhibition in cancer therapy (5 papers). Xiaoxing Feng is often cited by papers focused on Cancer Research and Treatments (12 papers), Neuroblastoma Research and Treatments (6 papers) and PARP inhibition in cancer therapy (5 papers). Xiaoxing Feng collaborates with scholars based in United States, China and United Kingdom. Xiaoxing Feng's co-authors include David W. Koh, Yiran Zhou, Mandi M. Hopkins, David W. Koh, John S. Bomalaski, Amanda Johnston, Mengwei Liu, Peter W. Szlosarek, Michael Sheaff and Pui Ying Chan and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer.

In The Last Decade

Xiaoxing Feng

25 papers receiving 638 citations

Peers

Xiaoxing Feng
Eduardo G. Cafferata Argentina
Neel Sengupta United Kingdom
Dapeng Ding China
Libo Yan China
Yuan Wu China
Jiateng Zhong China
Ki Cheong Park South Korea
Patricia Hentosh United States
Parviz Behnam‐Motlagh Sweden
Oleg Shuvalov Russia
Eduardo G. Cafferata Argentina
Xiaoxing Feng
Citations per year, relative to Xiaoxing Feng Xiaoxing Feng (= 1×) peers Eduardo G. Cafferata

Countries citing papers authored by Xiaoxing Feng

Since Specialization
Citations

This map shows the geographic impact of Xiaoxing Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoxing Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoxing Feng more than expected).

Fields of papers citing papers by Xiaoxing Feng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoxing Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoxing Feng. The network helps show where Xiaoxing Feng may publish in the future.

Co-authorship network of co-authors of Xiaoxing Feng

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoxing Feng. A scholar is included among the top collaborators of Xiaoxing Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoxing Feng. Xiaoxing Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Yang, Congyu Zhang, Qian Tong, & Xiaoxing Feng. (2022). Potential regulatory effects of CXCR2 and CPEB1 on cardiac cachexia. Tropical Journal of Pharmaceutical Research. 20(4). 709–714. 1 indexed citations
3.
Chan, Pui Ying, Melissa Phillips, Stephen Ellis, et al.. (2022). A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma. Pigment Cell & Melanoma Research. 35(4). 461–470. 21 indexed citations
4.
Szlosarek, Peter W., Akhila Wimalasingham, Melissa Phillips, et al.. (2021). Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer. Cancer Medicine. 10(19). 6642–6652. 14 indexed citations
5.
Wang, Jingyue, et al.. (2021). A Review of Prognosis Model Associated With Cardiogenic Shock After Acute Myocardial Infarction. Frontiers in Cardiovascular Medicine. 8. 754303–754303. 10 indexed citations
6.
Zhang, Longfei, et al.. (2021). Intelligent Human Body Posture Recognition and Its Comparative Study. Journal of Physics Conference Series. 1894(1). 12053–12053.
7.
Feng, Xiaoxing, et al.. (2020). Identification of X-ray Weld Defects under Artificial Intelligence Framework. 2020 5th International Conference on Mechanical, Control and Computer Engineering (ICMCCE). 1186–1189.
8.
Szlosarek, Peter W., Melissa Phillips, Jeremy Steele, et al.. (2020). Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. JTO Clinical and Research Reports. 1(4). 100093–100093. 23 indexed citations
9.
Harding, James J., Richard Kinh Gian, Imane El Dika, et al.. (2018). A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. Cancer Chemotherapy and Pharmacology. 82(3). 429–440. 32 indexed citations
10.
Phillips, Melissa, Teresa Szyszko, Peter A. Hall, et al.. (2018). Abstract B33: Expansion study of pegylated arginine deiminase (ADI-PEG20), pemetrexed, and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer (TRAP). Clinical Cancer Research. 24(17_Supplement). B33–B33. 1 indexed citations
11.
Lowery, Maeve A., Kenneth H. Yu, David P. Kelsen, et al.. (2017). A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Cancer. 123(23). 4556–4565. 63 indexed citations
12.
Zhao, Mengran, et al.. (2016). Identification and Characterization of Small Noncoding RNAs in Genome Sequences of the Edible FungusPleurotus ostreatus. BioMed Research International. 2016. 1–9. 28 indexed citations
13.
14.
Hopkins, Mandi M., et al.. (2015). Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells. International Journal of Oncology. 46(5). 2267–2276. 48 indexed citations
15.
16.
Feng, Xiaoxing & David W. Koh. (2013). Roles of Poly(ADP-Ribose) Glycohydrolase in DNA Damage and Apoptosis. International review of cell and molecular biology. 304. 227–281. 57 indexed citations
17.
Dillon, Simon T., Manoj Bhasin, Xiaoxing Feng, David W. Koh, & Sayed S. Daoud. (2013). Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity. Journal of Translational Medicine. 11(1). 239–239. 24 indexed citations
18.
19.
20.
Zhou, Yiran, Xiaoxing Feng, & David W. Koh. (2010). Enhanced DNA Accessibility and Increased DNA Damage Induced by the Absence of Poly(ADP-ribose) Hydrolysis. Biochemistry. 49(34). 7360–7366. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eduardo G. Cafferata Breakdown of academic impact, for papers by Neel Sengupta Breakdown of academic impact, for papers by Dapeng Ding Breakdown of academic impact, for papers by Libo Yan Breakdown of academic impact, for papers by Yuan Wu Breakdown of academic impact, for papers by Jiateng Zhong Breakdown of academic impact, for papers by Ki Cheong Park Breakdown of academic impact, for papers by Patricia Hentosh Breakdown of academic impact, for papers by Parviz Behnam‐Motlagh Breakdown of academic impact, for papers by Oleg Shuvalov
Rankless by CCL
2026